I am new to this group. I have been waiting for 20+ years to see a
cure or a real hope of a cure...What is happening seems to be faster
than the ADA who seems satisfied with the band aid of using insulin
instead of finding a real cure. How do I get my name on the list
for the trials? I have two grandsons who I hope never have to deal
with this desease personally. Thank you, would love to hear from
anyone on this situation --- In
nathanfaustmantrials@yahoogroups.com, "imcimc1" <curtieimc@...>
wrote:
>
> They have to automate the process. They cannot monitor even a
small
> group of people effectively day after day during the trial without
> automation. I would rather see this automation process get off
the
> ground now instead of after phase 1 of the trial is finished. At
> least the are working with some kind of vision and greater plan in
> mind. My fingers are crossed with this one.
>
> --- In nathanfaustmantrials@yahoogroups.com, "stilltypeone"
> <stilltypeone@> wrote:
> >
> > Sue, thanks for the info. I am still baffled that they chose to
> > spend time and money on the automation process, when it may be a
> > moot point.
> > If they can count T cells from hundreds of mice, can they not do
> the
> > same for such a small sample of humans?
> >
> >
> > --- In nathanfaustmantrials@yahoogroups.com, Sue root
> > <susan_root@> wrote:
> > >
> > > The procedure to separate and count the targeted T cells from
> > whole blood samples in humans takes 1 ½ days by hand. Seeing
that
> > they plan to ultimately take blood samples every other day from
the
> > patients to monitor the effect, and they will plan to have 40
> > patients in the trial with controls, the automation will make
this
> > possible in a timely manner by decreasing the procedure to only
> > about 6 hrs. More importantly, standardizing dosing in mice is
much
> > less of an issue compared to humans, even if we're talking 40
people
> > > Even though the NOD mouse is the best known animal model for
type
> > I diabetes, when dosing in mice, one doesn't have to deal with
> > variables such as body weight. The groups of mice are born at
the
> > same time, are the same size, and develop diabetes roughly the
same
> > time. Therefore, being able to standardize the dosing of BCG in
a
> > group of humans with such variables, will be a key factor for
> > success.
> > > What we do know is that the NOD mice have the same 2 defects
> > found in humans with type I diabetes and the treatment that Dr.
> > Faustman used targets and eliminates these defects.
> > >
> > >
> > > stilltypeone <stilltypeone@> wrote:
> > > Patsy, I think you are misunderstanding what I am
> > inferring.
> > > The point I am making is why spend so much time and money on a
> > > automation process that, in the end may end up as useless.
Kind
> of
> > > like the "cart before the horse". Why not do the initial trial
by
> > > hand, as the mouse trials were done. If sucessful, then move
on
> to
> > > scale this up to a larger group trial.
> > > I would not expect death from BCG injections, as it is used in
> > huge
> > > quantities for bladder cancer.
> > > The begining trial as I understand it will be 40 individuals.
I
> > > consider that "small". I realize that is a relative term.
> > > If asking questions is "grumbling" then I am guilty.
> > >
> > > --- In nathanfaustmantrials@yahoogroups.com, Patsy Van Huyck
> > > <patsy@> wrote:
> > > >
> > > > The answer in short is because if a mouse dies, nobody
cares.
> > > Just
> > > > think if the "small human trial" was a failure either due to
> > huge
> > > > complications or due to the lack of results. Do you think
that
> > > they
> > > > would just get to try again with another dose? The assay is
> very
> > > > important so that the trial can be successful, and we can
then
> > > move to
> > > > the next stage.
> > > >
> > > > We all want the cure to have been in 2002, but dealing with
the
> > > FDA is
> > > > tediously slow. Grumbling isn't going to get the research
done
> > > any more
> > > > quickly.
> > > >
> > > > Patsy
> > > >
> > > > >
> > > > > Re: NEJM Correspondence
> > > > >
> > >
> >
>
<http://groups.yahoo.com/group/nathanfaustmantrials/message/245;_ylc=
> > >
> >
>
X3oDMTJxMmg3MXB1BF9TAzk3MzU5NzE1BGdycElkAzE2NDEyMTQ1BGdycHNwSWQDMTcwN
> > >
> >
>
TA2MTY2MgRtc2dJZAMyNDUEc2VjA2Rtc2cEc2xrA3Ztc2cEc3RpbWUDMTE3MDU4NDUyMQ
> > > -->
> > > > >
> > > > >
> > > > >
> > > > > Posted by: "stilltypeone" stilltypeone@
> > > > > <mailto:stilltypeone@?Subject=%20Re%3A%20NEJM%
> > > 20Correspondence>
> > > > > stilltypeone <http://profiles.yahoo.com/stilltypeone>
> > > > >
> > > > >
> > > > > Sat Feb 3, 2007 6:57 pm (PST)
> > > > >
> > > > > Sue, can we agree that these trials will not proceed until
> > > > > the "automated assay" is completed?
> > > > > Did Faustman have this automated assay during the mouse
> trials?
> > > > > I am guessing the answer is no.
> > > > > So, why the need for automation for a small human trial?
> > > >
> > >
> >
>